Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (ATHA) is a clinical-stage biopharmaceutical company pioneering novel therapeutics targeting neurodegenerative diseases through modulation of the HGF system. This page aggregates official press releases, clinical trial updates, and strategic developments related to their pipeline of small molecule candidates.
Investors and researchers will find timely updates on regulatory milestones, partnership announcements, and scientific presentations. Key content includes progress reports on lead candidate fosgonimeton (ATH-1017) for Alzheimer's disease, updates on oral therapies ATH-1020 and ATH-1105, and analyses of biomarker-driven trial outcomes.
All materials are sourced directly from the company's investor relations communications and verified industry publications. Bookmark this page for streamlined access to Athira Pharma's latest advancements in neuroprotection research and therapeutic development.
Athira Pharma has placed Leen Kawas on temporary leave pending a review related to her doctoral research at Washington State University. Mark Litton, currently COO, will take over leadership responsibilities. An independent committee has been formed for the review. Despite this, the company remains confident in its lead drug ATH-1017, which has shown promising results in clinical trials for improving cognitive functions and addressing neurodegenerative diseases. Athira emphasizes its commitment to scientific integrity amidst this review process.
Athira Pharma (NASDAQ: ATHA) appointed Rachel Lenington as Chief Technology Officer, effective June 14, 2021. Lenington brings over 20 years of experience from organizations like Seagen Inc and the Bill & Melinda Gates Foundation. Her expertise in R&D, drug development, and commercialization is expected to bolster Athira's efforts in neurodegenerative disease treatments. CEO Leen Kawas expressed optimism about her leadership enhancing the company's product strategies. Athira focuses on developing small molecules to restore neuronal health, notably its lead candidate, ATH-1017, targeting Alzheimer’s and Parkinson’s dementia.
Athira Pharma (NASDAQ: ATHA) announced its participation in two upcoming investor conferences: the JMP Securities Life Sciences Conference on June 17, 2021, at 3:30 PM ET and the Raymond James Human Health Innovation Conference on June 21, 2021, at 1:20 PM ET. Management will engage in discussions about neurodegenerative diseases, focusing on new therapeutic targets for conditions like Alzheimer’s and Parkinson’s. Webcasts of the presentations will be available on the company’s website for 30 days post-event.
Athira Pharma, Inc. (NASDAQ: ATHA) has appointed Mark Worthington as General Counsel, effective June 1, 2021. Worthington brings extensive legal experience from 24 years at Summit Law Group, particularly in corporate finance and governance. His role is expected to bolster Athira’s strategic business growth, as cited by CEO Leen Kawas. Athira is focused on developing therapies aimed at neurodegenerative disorders, with its lead candidate, ATH-1017, targeting Alzheimer’s and Parkinson’s disease.
Athira Pharma (NASDAQ: ATHA) announced participation in the Jefferies Virtual Healthcare Conference on June 2, 2021, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021. CEO Leen Kawas will engage in a fireside chat and one-on-one investor meetings during these events. Details include the fireside chat at the Jefferies Conference at 4:30 PM ET and the Goldman Sachs Conference at 5:30 PM ET. Webcasts for both events are available on the Athira website, with archived replays accessible for at least 30 days following each event.
Athira Pharma, Inc. (NASDAQ: ATHA) reported financial results for Q1 2021, highlighting a net loss of $8.9 million, or $0.25 per share. The company's cash position improved to $357.7 million following a successful follow-on public offering, raising $103.5 million. Athira is advancing its clinical trials for ATH-1017 in treating Alzheimer’s and Parkinson’s disease dementia, with Phase 2 trials expected to start by late 2021. The company remains focused on developing small molecules aimed at neurodegeneration, maintaining a clear strategic plan and ample funding for future milestones.
Athira Pharma (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company, announced that CEO Leen Kawas, Ph.D., will participate in the Sachs 4th Annual Neuroscience Innovation Forum on April 28, 2021, at 8:30 a.m. PT. The panel titled “Progress in Alzheimer’s and Dementia” will focus on advancements in treating neurodegenerative diseases. The event will also feature notable experts from AZTherapies, NIH, Johnson & Johnson Innovation, and more. A recording will be available starting May 26, and further details can be found on Athira's website.
Athira Pharma (NASDAQ: ATHA) is hosting a webinar on April 15, 2021, at 1:30 p.m. PT to discuss its therapeutic approach targeting the HGF/MET pathway for neurodegeneration. Led by neurologist Marwan Sabbagh, M.D., the session will cover Alzheimer’s and dementia treatment landscapes and the role of hepatocyte growth factor in brain health. Kevin Church, Ph.D., will provide insights on Athira's lead candidate, ATH-1017, designed to enhance HGF/MET activity. Registration is available on Athira’s investor website, and a replay will be accessible for 30 days post-event.
Athira Pharma reported significant developments in its clinical trials and financial status as of March 25, 2021. The company is actively enrolling patients in LIFT-AD and ACT-AD studies for its investigational drug ATH-1017, aimed at treating Alzheimer’s disease. Notably, Athira raised $103.5 million in a follow-on public offering. Financially, the net loss for 2020 was $19.9 million, with cash reserves of $268.2 million expected to sustain operations through at least 2022. The firm anticipates IND submissions for Parkinson’s disease dementia and neuropsychiatric programs by the end of 2021.
Athira Pharma (NASDAQ: ATHA), a biopharmaceutical company focused on neuronal health, announced that its CEO, Leen Kawas, will participate in a virtual fireside chat at Stifel’s 3rd Annual CNS Conference on April 1, 2021, at 9:00 am ET. The event will be accessible via a live webcast on Athira's investor relations website, with an archived replay available for 90 days post-event. Athira is advancing its lead candidate, ATH-1017, targeting Alzheimer's and Parkinson's dementia, aiming to alter the course of neurological diseases and enhance cognitive abilities.
